pteridines has been researched along with Malignant Melanoma in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine." | 7.67 | Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 6.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 5.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| " We used an exploratory study into plasma concentrations of large neutral amino acids, 5-hydroxyindolacetic acid (5-HIAA), total biopterin (BIOP) and neopterin (NEOP) in 40 high-risk melanoma patients." | 5.11 | Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations. ( Bannink, M; Eggermont, AM; Fekkes, D; Kruit, WH; Mulder, PG; Stoter, G; Van Gool, AR; van Ojik, HH, 2004) |
| "The effect was studied of a number of synthetic indoleamines, pteridines, beta-carbolines, of AVT and of crude extracts from rat and ovine pineal glands on human melanoma cells in vitro." | 3.67 | Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. ( Bartsch, C; Bartsch, H; Ebels, I; Flehmig, B; Noteborn, HP; Salemink, CA, 1987) |
| "In two groups of patients with checked diagnoses of the malignant melanoma and Hodgkin's disease we followed changes of the renal excretion of two major pterines, neopterine and biopterine." | 3.67 | Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease. ( Andrysek, O; Cernovská, I; Vasícková, M; Zitko, M, 1986) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 2.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 1.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Theodosakis, N | 1 |
| Micevic, G | 1 |
| Langdon, CG | 1 |
| Ventura, A | 1 |
| Means, R | 1 |
| Stern, DF | 1 |
| Bosenberg, MW | 1 |
| Cholewa, BD | 2 |
| Pellitteri-Hahn, MC | 1 |
| Scarlett, CO | 1 |
| Ahmad, N | 2 |
| Ndiaye, MA | 1 |
| Huang, W | 1 |
| Liu, X | 1 |
| Schöffski, P | 1 |
| Blay, JY | 1 |
| De Greve, J | 1 |
| Brain, E | 1 |
| Machiels, JP | 1 |
| Soria, JC | 1 |
| Sleijfer, S | 1 |
| Wolter, P | 1 |
| Ray-Coquard, I | 1 |
| Fontaine, C | 1 |
| Munzert, G | 1 |
| Fritsch, H | 1 |
| Hanft, G | 1 |
| Aerts, C | 1 |
| Rapion, J | 1 |
| Allgeier, A | 1 |
| Bogaerts, J | 1 |
| Lacombe, D | 1 |
| Mohammad, KS | 1 |
| Javelaud, D | 1 |
| Fournier, PG | 1 |
| Niewolna, M | 1 |
| McKenna, CR | 1 |
| Peng, XH | 1 |
| Duong, V | 1 |
| Dunn, LK | 1 |
| Mauviel, A | 1 |
| Guise, TA | 1 |
| de Oliveira, JC | 1 |
| Brassesco, MS | 1 |
| Pezuk, JA | 1 |
| Morales, AG | 1 |
| Valera, ET | 1 |
| Montaldi, AP | 1 |
| Sakamoto-Hojo, ET | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Kapoor, S | 1 |
| Van Gool, AR | 1 |
| van Ojik, HH | 1 |
| Kruit, WH | 1 |
| Bannink, M | 1 |
| Mulder, PG | 1 |
| Eggermont, AM | 1 |
| Stoter, G | 1 |
| Fekkes, D | 1 |
| Gregory, CR | 1 |
| Harmon, BG | 1 |
| Latimer, KS | 1 |
| Hafner, S | 1 |
| Campagnoli, RP | 1 |
| McManamon, RM | 1 |
| Steffens, WL | 1 |
| Bartsch, H | 1 |
| Bartsch, C | 1 |
| Noteborn, HP | 1 |
| Flehmig, B | 1 |
| Ebels, I | 1 |
| Salemink, CA | 1 |
| Zitko, M | 1 |
| Andrysek, O | 1 |
| Cernovská, I | 1 |
| Vasícková, M | 1 |
| Pomerantz, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149] | Phase 2 | 76 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pteridines and Malignant Melanoma
| Article | Year |
|---|---|
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo | 2010 |
Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations.
Topics: Adult; Aged; Amino Acids; Biopterins; Drug Administration Schedule; Female; Humans; Hydroxyindoleace | 2004 |
10 other studies available for pteridines and Malignant Melanoma
| Article | Year |
|---|---|
p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; MAP Kinase Kinas | 2017 |
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Heterogeneous-Nuclear Ribonucleoprotein Group C; Humans; Mela | 2014 |
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cell Pr | 2017 |
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
Topics: Animals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progressio | 2011 |
In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2012 |
New inhibitors of Polo-like kinase 1 function and their emerging role in attenuating tumor growth in systemic malignancies.
Topics: Cell Cycle Proteins; Humans; Melanoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pt | 2012 |
Malignant chromatophoroma in a canebrake rattlesnake (Crotalus horridus atricaudatus).
Topics: Animals; Chromatography, Paper; Chromatophores; Crotalus; Female; Histocytochemistry; Immunohistoche | 1997 |
Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances.
Topics: Animals; Brain; Carbolines; Cell Count; Cell Division; Cell Line; Growth Inhibitors; Humans; Indoles | 1987 |
Renal excretion of neopterine and biopterine in patients with malignant melanoma and Hodgkin's disease.
Topics: Biopterins; Chromatography, Thin Layer; Female; Hodgkin Disease; Humans; Kidney; Male; Melanoma; Neo | 1986 |
Tyrosine hydroxylation catalyzed by mammalian tyrosinase: an improved method of assay.
Topics: Animals; Cricetinae; Dihydroxyphenylalanine; In Vitro Techniques; Kinetics; Melanoma; Neoplasms, Exp | 1964 |